Imexpharm faces delisting risk as Chinese investor moves to take control
Shares of Imexpharm Pharmaceutical JSC (HoSE: IMP) could face delisting risks as a Chinese pharmaceutical group moves to raise its ownership to a controlling level, potentially reducing the company’s free float below regulatory requirements.
Companies - Tue, March 31, 2026 | 1:19 pm GMT+7
- Editor’s Picks
-
EVNGENCO3 eyes $270 mln flexible LNG power plant in northern Vietnam
-
TikTok Shop narrows gap with Shopee as Vietnam e-commerce becomes duopoly
-
Samsung Thai Nguyen, TTC solar plant become first participants in Vietnam's direct power purchase mechanism
-
Taiwanese FDI into Vietnam: The shift of the value chain
-
Thailand’s TCC Group eyes logistics, recycling in Vietnam
- Most Read
1
2
Singapore's leading firms seek to expand investments in Vietnam
Economy - Update 2 week ago
3
- Editor’s Picks
-
EVNGENCO3 eyes $270 mln flexible LNG power plant in northern Vietnam
-
TikTok Shop narrows gap with Shopee as Vietnam e-commerce becomes duopoly
-
Samsung Thai Nguyen, TTC solar plant become first participants in Vietnam's direct power purchase mechanism
-
Taiwanese FDI into Vietnam: The shift of the value chain
-
Thailand’s TCC Group eyes logistics, recycling in Vietnam
Not found block 'box_opinion'
